Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies

ABSTRACTEfficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in antigen identification, with the aim of understanding mechanisms of...

Full description

Saved in:
Bibliographic Details
Main Authors: Belen Aparicio (Author), Patrick Theunissen (Author), Sandra Hervas-Stubbs (Author), Puri Fortes (Author), Pablo Sarobe (Author)
Format: Book
Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c6814b50000f44d59d15719a8a8fda2c
042 |a dc 
100 1 0 |a Belen Aparicio  |e author 
700 1 0 |a Patrick Theunissen  |e author 
700 1 0 |a Sandra Hervas-Stubbs  |e author 
700 1 0 |a Puri Fortes  |e author 
700 1 0 |a Pablo Sarobe  |e author 
245 0 0 |a Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies 
260 |b Taylor & Francis Group,   |c 2024-12-01T00:00:00Z. 
500 |a 10.1080/21645515.2024.2303799 
500 |a 2164-554X 
500 |a 2164-5515 
520 |a ABSTRACTEfficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in antigen identification, with the aim of understanding mechanisms of response to immunotherapy and to design safer and more efficient strategies. In addition to classical tumor-associated antigens identified during the last decades, implementation of next-generation sequencing methodologies is enabling the identification of neoantigens (neoAgs) arising from mutations, leading to the development of new neoAg-directed therapies. Moreover, there are numerous non-classical tumor antigens originated from other sources and identified by new methodologies. Here, we review the relevance of neoAgs in different immunotherapies and the results obtained by applying neoAg-based strategies. In addition, the different types of non-classical tumor antigens and the best approaches for their identification are described. This will help to increase the spectrum of targetable molecules useful in cancer immunotherapies. 
546 |a EN 
690 |a Tumor neoantigens 
690 |a mutations 
690 |a non-classical tumor antigens 
690 |a ribosome profiling 
690 |a immunopeptidomics 
690 |a Immunologic diseases. Allergy 
690 |a RC581-607 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) 
787 0 |n https://www.tandfonline.com/doi/10.1080/21645515.2024.2303799 
787 0 |n https://doaj.org/toc/2164-5515 
787 0 |n https://doaj.org/toc/2164-554X 
856 4 1 |u https://doaj.org/article/c6814b50000f44d59d15719a8a8fda2c  |z Connect to this object online.